{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "exchange": "PNK", "shortName": "SOSEI GROUP CORP", "longName": "Sosei Group Corporation", "messageBoardId": "finmb_1266465", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "REGULAR", "regularMarketChangePercent": -3.7476234, "regularMarketPrice": 20.29, "firstTradeDateMilliseconds": 1378301400000, "priceHint": 2, "fiftyTwoWeekLowChange": 11.850001, "fiftyTwoWeekLowChangePercent": 1.4040287, "fiftyTwoWeekRange": "8.44 - 21.28", "fiftyTwoWeekHighChange": -0.9899998, "fiftyTwoWeekHighChangePercent": -0.046522543, "fiftyTwoWeekLow": 8.44, "fiftyTwoWeekHigh": 21.28, "trailingAnnualDividendRate": 0.0, "trailingPE": 676.3334, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 0.03, "sharesOutstanding": 81923000, "bookValue": 710.594, "fiftyDayAverage": 18.726261, "fiftyDayAverageChange": 1.5637398, "fiftyDayAverageChangePercent": 0.083505176, "twoHundredDayAverage": 13.54444, "twoHundredDayAverageChange": 6.7455606, "twoHundredDayAverageChangePercent": 0.4980317, "marketCap": 1662217728, "priceToBook": 0.028553577, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "regularMarketChange": -0.789999, "regularMarketTime": 1684249938, "regularMarketDayHigh": 20.29, "regularMarketDayRange": "20.29 - 20.29", "regularMarketDayLow": 20.29, "regularMarketVolume": 800, "regularMarketPreviousClose": 21.08, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "Other OTC", "financialCurrency": "JPY", "regularMarketOpen": 20.29, "averageDailyVolume3Month": 1590, "averageDailyVolume10Day": 101, "displayName": "Sosei", "symbol": "SOLTF"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "PMO Hanzomon", "address2": "11th Floor 2-1 Kojimachi Chiyoda-ku", "city": "Tokyo", "zip": "102-0083", "country": "Japan", "phone": "81 3 5210 3290", "website": "https://soseiheptares.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.", "fullTimeEmployees": 202, "companyOfficers": [{"maxAge": 1, "name": "Mr. Shinichi  Tamura", "age": 73, "title": "Founder & Chairman", "yearBorn": 1949, "fiscalYear": 2021, "totalPay": {"raw": 2414408, "fmt": "2.41M", "longFmt": "2,414,408"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chris  Cargill", "age": 38, "title": "Representative Exec. Officer, Pres, CEO & Director", "yearBorn": 1984, "fiscalYear": 2021, "totalPay": {"raw": 1700391, "fmt": "1.7M", "longFmt": "1,700,391"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Hironoshin  Nomura", "title": "Sr. VP of Investor Relations, VP & Corp. Strategy, Exec. Officer and CFO", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kieran  Johnson F.C.A.", "title": "Exec. Officer, VP & Chief Accounting Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Miles  Congreve", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kazuhiko  Yoshizumi", "age": 68, "title": "Exec. Officer, VP & Chief Compliance Officer", "yearBorn": 1954, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Shinichiro  Nishishita", "title": "VP of Investor Relations & Head of Regulatory Disclosures", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Stacey  Southall", "title": "Associate Director & Head of Biophysics", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Candelle  Chong", "title": "Exec. Officer, Exec. VP & Chief of Staff", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Matt  Barnes", "title": "Head of Drug Discovery, Exec. Officer, VP, Pres of Heptares Therapeutics Ltd. & Head of UK R&D", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}